Norbert VEY
MD
-
Head of the Leukemias Treatment Unit and « Translational Medicine in Hematology » Team at IPC | Co-director of the « Evaluation of Therapeutic Oncology and Hematology » unit at IPC | Professor in hematology at Aix-Marseille University
AMU, IPC
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
Have a look on our testimonies
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
Nicolas SCHLEINITZ
AP-HM, AMU
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Catherine FARNARIER
AP-HM
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
Jean-Paul BORG
AMU, IPC, CRCM
your commitment to MI